Our platform product, Allo-IMmunotherapy (AIM) is an allogeneic, “off-the-shelf”, cell-based therapy for solid tumors that does not require complex or costly cell engineering.  AIM is delivered directly to the tumor and is designed to remain at the tumor site to maximize activity while avoiding systemic toxicity.  AIM serves as bait for the immune system by triggering inflammation, and an influx of activated immune cells to the tumor site.  AIM reboots the immune system and increases anti-tumor activity to ripen the tumor for combination treatment with  checkpoint inhibitor immunotherapy, surgery, chemotherapy or other agents.  

​

THE AIM ADVANTAGE:

• broad application across solid tumor types, including hard- to- treat/recurrent/metastatic disease, unresectable tumors and pediatric indications

• designed to remain at the site of the tumor/metastases

• easy integration into current treatment regimens

• no requirement to halt current treatment regimen during AIM therapy

• partner of choice: no systemic or overlapping toxicity with common therapies

• ability to re-dose to induce a prime/boost effect

• no wait time to treatment for patients

• no lymphodepletion required for patients